Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwideBOSTON, Jan. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the gene therapy collaboration they announced with Biogen in May 2021. Together, the companies aimed to redefine the industry standard for manufacturing recombinant adeno ...

A big part of the allure of investing in small and mid-cap stocks is their potential to be worth much more in the future. After all, it's a lot more probable that a company that's only worth a few billion dollars will grow its business enough to double in value than it is for a company that's already worth hundreds of billions. But smaller stocks also come with more risk, as they're often unproven and not well-established businesses.Ginkgo Bioworks (DNA -0.57%) is a mid-cap company that has some promising l ...

Ginkgo Bioworks Holdings Inc. (NYSE:DNA) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Director Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Poon Mah - TD Cowen Derik Bruin - BofA Securities Michael Freeman - Raymond James E.V. Koslosky - Goldman Sachs Megan LeDuc Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 ____________________________________ ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2023 Earnings Conference Call August 9, 2023 5:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good evening. I am Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. I’ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Gaurav Goparaju - Berenberg Bank Ivy Kozlowski - Goldman Sachs Anna Marie Wagner Good afternoon. I'm Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Fou ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40097 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of Registrant as specified in its Charter) Delaware 87-2652913 (St ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Anna Marie Wagner - SVP, Corporate Development Jason Kelly - Co-Founder & CEO Mark Dmytruk - CFO Conference Call Participants Matthew Sykes - Goldman Sachs Rahul Sarugaser - Raymond James Tejas Savant - Morgan Stanley Steve Mah - Cowen Madeline - William Blair Mark Massaro - BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. ...